Appearance of extrapyramidal symptoms in adolescent psychiatry patients during COVID‐19 infection
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Medical Virology"
DOI: 10.1002/jmv.28556
Abstract: Since the start of the pandemic, there has been an increase in the incidence of psychiatric morbidity among those infected with coronavirus disease 2019 (COVID‐19) and those indirectly affected by COVID‐19. There has been a… read more here.
Keywords: covid infection; infection; patients covid; extrapyramidal symptoms ... See more keywords
The Incidence and Economic Burden of Extrapyramidal Symptoms in Patients with Schizophrenia Initiating Atypical Antipsychotics in a Commercially Insured Population
Sign Up to like & getrecommendations! Published in 2022 at "CNS Spectrums"
DOI: 10.1017/s1092852922000219
Abstract: Abstract Background Extrapyramidal symptoms (EPS) affect 15% to 30% of patients with schizophrenia treated with antipsychotics and have been associated with poor patient outcomes. Objectives To examine the incidence and economic burden of EPS in… read more here.
Keywords: extrapyramidal symptoms; non eps; patients schizophrenia; economic burden ... See more keywords
The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of medical economics"
DOI: 10.1080/13696998.2021.2019501
Abstract: BACKGROUND Extrapyramidal symptoms (EPS) are common side effects of second generation antipsychotics (SGA), they can negatively impact patient quality of life, and are associated with increased morbidity and mortality. This study examined the incidence and… read more here.
Keywords: generation antipsychotics; patients schizophrenia; second generation; extrapyramidal symptoms ... See more keywords
Comparison of Extrapyramidal Symptoms Among Outpatients With Schizophrenia on Long-Acting Injectable Antipsychotics
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Psychopharmacology"
DOI: 10.1097/jcp.0000000000001580
Abstract: Abstract Background Extrapyramidal symptoms (EPSs) are adverse effects of antipsychotics. Different risks of EPSs have been attributed to the 3 classes of antipsychotics. This study aimed to assess EPS in a clinical sample of schizophrenia… read more here.
Keywords: extrapyramidal symptoms; among outpatients; symptoms among; esrs scores ... See more keywords